Good morning, welcome to the reconvened 2026 annual meeting of stockholders of vTv Therapeutics. I will now hand the call over to Paul Sekhri. Paul, you may proceed. Good morning. I'm Paul Sekhri, Chairman of the Board, President, and Chief Executive Officer of vTv Therapeutics, I'll be presiding over this meeting. On behalf of the Board and the officers of vTv Therapeutics, I'm pleased to welcome you to the reconvened 2026 annual meeting of stockholders. It is 11:00 A.M., in accordance with the bylaws of the company, I call this meeting to order. We appreciate you attending our annual meeting virtually. All of our stockholders of record as of close of business of April 14, 2026, were mailed a notice with the proxy notice and proxy card, including instructions for how to access our proxy statement and annual report via the Internet. Copies of our proxy statement and annual report are available on our website for download. Before proceeding to the business of the meeting, I'd like to introduce you to the other participants in today's meeting. Ms. Betzy Keiley, our Executive Vice President and General Counsel, will act as Secretary of the Meeting and will make a written record of the proceedings. Mr. Louis Larsen of Broadridge has been appointed as Inspector of Election in accordance with the company's bylaws. He will certify the counts of votes cast in the election of directors and the motions to be voted upon at this meeting. The named proxy holders for this meeting are Dr. Michael Tung, our Chief Financial Officer, and me. This meeting is held pursuant to a printed notice mailed on April 28, 2026, and a supplemental notice mailed on June 10, 2026, to each stockholder of record on April 14, 2026, who is entitled to vote. A list of stockholders entitled to vote at the meeting has been available at the company's executive offices for the past 10 days. All documents concerning the call and notice of this meeting will be filed with records of the company. There are approximately 3.9 million shares of our Class A and Class B common stock issued and outstanding and entitled to vote at this meeting. Of that number, approximately 2.9 million shares are represented at this meeting by proxies returned through Monday evening, June 25. As a result, I certify that the holders of a sufficient number of shares are present to represent a quorum. With the quorum present, we will proceed with the business of the meeting. On behalf of the Board, I would also like to express my appreciation to all stockholders who are attending this meeting and those who are unable to attend but returned their proxies. The first order of business is a description of the matters to be voted upon at today's meeting. At this meeting, the stockholders were asked to vote on the following matters: to elect seven directors of the company, to ratify the Board's appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the current fiscal year, which ends on December 31st, 2026, and approval on an advisory basis of the compensation of our named executive officers as described in the proxy statement. First matter submitted to the shareholders was the election of seven directors to the company's board of directors. The votes submitted by the proxy holders in response to proxies that were received through Thursday evening cast a plurality of votes for the seven nominees. Based on the votes cast, Srinivas Akkaraju, Raymond Cheong, Fahed Al Marzooqi, Richard S. Nelson, Anne M. Phillips, Paul Sekhri, and Daniel K. Spiegelman have been elected as directors. The next matter submitted to stockholders for action was the ratification of the appointment by the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the company for the current fiscal year, which ends on December 31st. The votes of the proxy holders in response to proxies that were received through Thursday evening cast not less than approximately 2.9 million votes to ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for the company. That number exceeds a majority of the number of total votes of all Class A and Class B shares outstanding. Therefore, Ernst & Young has been approved as the company's independent registered public accounting firm for the current fiscal year, which ends on December 31st, 2026. The final matter submitted to stockholders for action was the non-binding advisory vote to approve the compensation of our named executive officers. The votes of the proxy holders in response to proxies that were received through Thursday evening cast not less than 680,000 votes to approve the compensation of our named executive officers. That number does not exceed a majority of the number of total votes of all Class A and Class B shares outstanding. Therefore, the proposal has not been approved by the stockholders. There being no other business, I move that this meeting be adjourned. I second the motion to adjourn. The motion has been made and seconded. This meeting is adjourned. Again, I would like to express my appreciation to stockholders who attended this meeting as well as those who submitted their proxies but were not able to be present. Hope everyone has an enjoyable weekend. Thank you. The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.